Is an electronic signature valid?

Yes — under the ESIGN Act and UETA, an electronic signature is enforceable if the signing shows intent, consent to electronic records, attribution to the signer, and the record can be retained and reproduced.

When is notarization or witnesses required?

Notarization or witnesses depend on state law and document purpose; some jurisdictions require notarized acknowledgements for certain legal filings, while consent forms rarely require notarization unless requested for evidentiary purposes.

How does donor withdrawal work?

Withdrawal typically stops future testing and sharing; samples already used or distributed may not be retractable. Agreements should define whether stored samples will be destroyed, de-identified, or retained for regulatory obligations and under what notice period.

Can minors or guardians provide consent?

Minors generally cannot consent for themselves; a parent or legal guardian must sign. Agreements should include fields for guardian identification and any assent procedures and follow applicable state laws governing research involving minors.

What methods verify signer identity?

Acceptable methods include government ID review, in-person verification, RON identity proofing, or multi-factor authentication for e-signatures. Level of verification should match sensitivity of genetic data and applicable privacy standards.

Does HIPAA apply to this agreement?

If the agreement involves protected health information in clinical settings, HIPAA applies and a business associate agreement may be required; research settings often require additional IRB and privacy safeguards beyond HIPAA.

Electronic Signature
Templates
Legal
Approved DNA Agreement

Approved DNA Agreement

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

APPROVED DNA AGREEMENT

This Approved DNA Agreement ("Agreement") is entered into as of by and between Provider Name: (an entity type: Individual Corporation Other) located at , and Client Name: (an entity type: Individual Corporation Other) located at .

RECITALS

WHEREAS, Provider operates facilities and laboratories capable of performing DNA analysis, genetic marker testing, and related laboratory services in accordance with generally accepted laboratory practices;

WHEREAS, Client desires Provider to perform the testing, analysis, storage, and limited research uses described herein for samples provided by Client, and Provider is willing to perform such services subject to the terms and conditions of this Agreement;

WHEREAS, the parties intend to define ownership, permitted uses, confidentiality, retention, and disposition of biological samples and genetic information derived therefrom.

NOW, THEREFORE, in consideration of the mutual covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:

1. DEFINITIONS

"Sample" means any biological material provided by or on behalf of Client to Provider for analysis, including but not limited to blood, saliva, tissue, or extracted DNA. "Data" means all raw, processed, and interpreted genetic information, reports, electronic files, and metadata generated by Provider from a Sample. "Permitted Uses" are those uses expressly set forth in Section 4.

2. SCOPE OF SERVICES

Provider shall perform DNA testing and analysis services described as follows:

Description of Tests / Services

Samples shall be identified by Client by the following identifier or format: . Collection date for each Sample shall be recorded as: .

3. SAMPLE SUBMISSION, HANDLING AND CHAIN OF CUSTODY

Client shall package and label Samples in accordance with Provider's sample submission procedures. Provider shall maintain a chain of custody log for each Sample and shall exercise reasonable care in handling Samples. Provider's obligation is limited to services expressly set forth herein and does not include liability for improper collection, labeling, or transport of Samples by Client or third parties engaged by Client.

4. OWNERSHIP; PERMITTED USES; LICENSE

Except as expressly provided below, Client retains ownership of the original Sample. Provider retains ownership of laboratory-developed methods, processes, proprietary algorithms, and any derivative or aggregated Data that are Provider's confidential methodologies. Provider grants Client a non-exclusive, non-transferable license to Data delivered to Client solely for Client's internal diagnostic, research, or legal purposes as specified in this Agreement and subject to the limitations herein.

Permitted Uses (select applicable):

Diagnostic and clinical decision-making Research and internal validation Educational and training purposes

If Client selects research uses, Client represents and warrants that any use involving human subjects or publication will comply with applicable ethical, legal, and regulatory requirements and will not identify individual subjects without explicit consent.

5. CONFIDENTIALITY AND DATA SECURITY

Each party shall maintain the confidentiality of the other's Confidential Information. "Confidential Information" includes non-public Data, Sample identifiers, and business information. Provider shall implement industry-standard administrative, technical, and physical safeguards to protect Data against unauthorized access, disclosure, alteration, or destruction. Provider shall notify Client promptly upon discovery of any unauthorized access reasonably likely to materially affect Client's Data.

6. DATA RETENTION AND DESTRUCTION

Provider will retain Samples and Data for the period specified below unless Client directs earlier destruction in writing. Absent written instruction, Provider will retain Samples for .

Disposition Instructions (if any)

7. REPORTING; ERRORS AND CORRECTIONS

Provider will deliver Results to Client in written or electronic form, identifying assay performed, methodology, findings, and applicable interpretation. Client shall notify Provider in writing of any suspected error within thirty (30) days of receipt of Results. Provider will investigate and, where an error is demonstrated, correct the Results at Provider's expense. Provider's obligation under this Section is Client's exclusive remedy for erroneous Results.

8. FEES, PAYMENT, AND TAXES

Total Fee Payment Terms

Except as otherwise stated, fees are exclusive of applicable taxes and duties. Client shall be responsible for any such taxes imposed by law.

9. REPRESENTATIONS AND WARRANTIES

Each party represents and warrants that it has full power and authority to enter into this Agreement and to perform its obligations hereunder. Client represents that it has the right to submit Samples and authorize the testing and use of the resulting Data as set forth in this Agreement.

10. INDEMNIFICATION

Client shall indemnify, defend, and hold harmless Provider and its officers, directors, employees, and agents from and against any third-party claims, damages, liabilities, and expenses arising out of Client's breach of this Agreement, Client's improper collection or labeling of Samples, or Client's use of Data inconsistent with the Permitted Uses. Provider shall indemnify Client for claims caused by Provider's gross negligence or willful misconduct in performing services under this Agreement.

11. LIMITATION OF LIABILITY

EXCEPT FOR LIABILITY ARISING FROM GROSS NEGLIGENCE, WILLFUL MISCONDUCT, OR INDEMNIFICATION OBLIGATIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. PROVIDER'S AGGREGATE LIABILITY ARISING FROM OR RELATING TO THIS AGREEMENT SHALL NOT EXCEED THE AMOUNTS ACTUALLY PAID BY CLIENT TO PROVIDER UNDER THIS AGREEMENT DURING THE TWELVE (12) MONTHS PRECEDING THE EVENT GIVING RISE TO THE CLAIM.

12. COMPLIANCE WITH LAW

Each party agrees to comply with applicable laws, regulations, and professional standards governing the collection, transportation, handling, testing, reporting, and storage of biological Samples and genetic Data.

13. NOTICES

All notices required or permitted under this Agreement shall be in writing and delivered to the addresses below by certified mail, courier, or email (with confirmation):

Notice to Provider - Attention / Address Notice to Client - Attention / Address

14. AMENDMENT; WAIVER; COUNTERPARTS

This Agreement may be amended only by a written instrument signed by authorized representatives of both parties. No waiver of any provision shall be effective unless in writing and signed by the waiving party. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

15. GOVERNING LAW; ENTIRE AGREEMENT; SEVERABILITY

This Agreement shall be governed by and construed in accordance with the laws of the jurisdiction designated below without regard to its conflicts of law rules. This Agreement, including all exhibits and schedules hereto, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings. If any provision is held invalid or unenforceable, the remaining provisions shall remain in full force and effect.

Governing law (State or jurisdiction)

16. AUDIT; RECORDS

Upon reasonable notice and during normal business hours, Provider shall permit Client or an independent auditor designated by Client to inspect Provider's records and facilities insofar as they pertain to Client's Samples or Data, to the extent necessary to verify Provider's compliance with this Agreement and subject to reasonable confidentiality protections.

17. MISCELLANEOUS

If either party is restricted from performing its obligations due to force majeure events beyond its reasonable control, that party's obligations shall be suspended for the duration of the event. Any provision that expressly or by implication is intended to survive termination shall survive.

ACKNOWLEDGMENTS

Client acknowledges that genetic information may have implications for family members and that Client has had an opportunity to obtain independent counsel regarding testing and use of Data. Client hereby authorizes Provider to perform the services described in this Agreement and to use the Data consistent with the Permitted Uses checked above.

Client acknowledges and agrees to the terms of this Agreement Provider acknowledges and agrees to the terms of this Agreement

Provider

Print Name:

By:

Date:

Client

Print Name:

By:

Date:

What the Approved DNA Agreement Covers

The Approved DNA Agreement is a legally binding consent and transfer document used when individuals, laboratories, clinics, or researchers need to authorize collection, testing, storage, or transfer of genetic material and related data. It sets terms for sample ownership, permitted uses, data sharing, confidentiality, and disposition of biological material and results. The agreement also documents consent for genetic testing, any limitations on downstream research or commercialization, and allocation of responsibilities among parties. Use this form to create a clear record of permissions and conditions required for compliant handling of DNA samples and genetic information.

Why an Approved DNA Agreement Matters

An Approved DNA Agreement clarifies consent, reduces legal ambiguity, and documents permitted uses of genetic material and data. Clear terms protect participant privacy, help satisfy HIPAA and research compliance requirements, and establish responsibilities for sample custody, testing, and data sharing.

Who Typically Uses an Approved DNA Agreement

Typical users for an Approved DNA Agreement include clinical providers, research institutions, diagnostic laboratories, biobanks, and individual sample donors.

Clinical research teams drafting participant consent and sample transfer provisions for observational or interventional studies.
Diagnostic laboratories documenting chain-of-custody, testing permissions, and third-party reporting obligations.
Biobanks and commercial labs establishing storage, future use, and commercialization terms with donors or partners.

Use the agreement to align expectations among stakeholders, document consent choices, and reduce administrative friction during collection, testing, transfer, and storage.

Core Sections to Include in the Agreement

Essential sections in an Approved DNA Agreement define rights, restrictions, and procedures for sample collection, testing, data use, and disposition to ensure legal and ethical compliance.

Consent Scope

Specify who consents, the precise types of genetic tests authorized, any age or capacity limitations, and whether consent covers future unspecified research or remains limited to current purposes.

Sample Ownership

Clarify ownership or custodial rights for biological material, whether donors retain property rights, and any transfer or licensing permissions granted to laboratories or researchers.

Use Restrictions

List permitted uses, research exclusions, commercialization constraints, and procedures requiring separate approvals prior to any secondary use, recontact, or linkage of genetic data.

Data Sharing

Define data access rights, de-identification standards, permitted recipients, third-party transfer rules, and obligations under HIPAA and institutional review board approvals.

Retention & Disposal

State retention period for samples and data, conditions for secure disposal or anonymization, and custodial responsibilities after study close or donor withdrawal.

Liability & Indemnity

Allocate responsibility for sample mishandling, inaccurate results, regulatory noncompliance, and include indemnity, insurance, and limitation of liability clauses as appropriate.

Step-by-Step: Completing an Approved DNA Agreement

Follow these steps to complete and validate an Approved DNA Agreement for collection, transfer, and testing of genetic samples.

01

Prepare form: Gather donor ID, consent choices, and recipient details.
02

Complete fields: Enter information accurately and select consent scope.
03

Authenticate signer: Verify identity and obtain signature or electronic consent.
04

Record retention: Store executed copy and update custody logs.

How Execution and Routing Typically Flow

Typical routing for an Approved DNA Agreement moves from collection to testing to storage with documented handoffs and audit records.

Collection: Sample obtained and chain-of-custody initiated.
Testing: Laboratory performs authorized analyses per consent.
Reporting: Results delivered to authorized parties under disclosure rules.
Storage/Disposal: Samples archived or securely destroyed per agreement.

Technical Requirements for Digital Completion and Submission

Digital completion and eSubmission require secure platforms that support signatures, identity verification, and tamper-evident audit trails.

File Formats: PDF/A and DOCX supported.
Authentication: Email, SMS OTP, or KBA.
Integrations: EHRs, LIMS, cloud storage.

Security and Compliance Essentials

Encryption: TLS 1.2/1.3 in transit; AES-256 at rest.

Audit Trail: Timestamps, IP, and action history.

Access Controls: Role-based access and MFA options.

HIPAA: BAA required for PHI handling.

21 CFR Part 11: Compliant options for FDA-regulated records.

Certifications: SOC 2, ISO 27001, PCI DSS.

Common Preparation Errors to Avoid

Ambiguous consent language that fails to specify permitted uses and future research rights, leading to disputes over secondary data use and commercialization.
Mismatched signer identity or missing verification steps, which can invalidate consent and create regulatory exposure for laboratories or institutions.
Incomplete chain-of-custody records or poor sample labeling, increasing risk of sample misidentification and erroneous test results.
Failure to include data sharing or recontact permissions, resulting in inability to share findings or reconsent participants for follow-up studies.

Potential Penalties and Legal Risks

Privacy Violation: HIPAA violations can result in fines and corrective actions.

Invalid Consent: Poorly executed consent may render testing unlawful.

Chain-of-Custody Break: Loss or tampering can affect admissibility and liability.

Regulatory Fines: Research noncompliance can trigger sanctions or funding loss.

Data Breach Costs: Notification, remediation, and litigation expenses possible.

Civil Liability: Wrongful disclosure or misuse can lead to lawsuits.

Key Dates and Response Deadlines to Track

Key dates and response windows govern consent effectiveness, withdrawal, sample disposition, and data access requests; track these carefully.

Effective Date of Consent:

Enter MM/DD/YYYY; determines when authorized activities may begin.

Withdrawal Notice Period:

Specify how to withdraw and the effect on stored samples.

Sample Retention Deadline:

State number of years or specific end date for storage.

Data Access Request Window:

Provide timeframe for responding to access or amendment requests.

Notarization Expiration:

If notarized, note any state-specific validity or re-execution requirements.

Example Uses of an Approved DNA Agreement

Real-world examples show how Approved DNA Agreements support clinical testing, research collaborations, and legal evidence handling while reducing disputes.

Clinical Testing

A regional hospital used an Approved DNA Agreement to standardize patient consent for hereditary testing across multiple clinics.

Improved consent clarity and sample tracking.
The agreement reduced administrative delays, ensured HIPAA-compliant handling of PHI, and documented patient choices about future research use, enabling the hospital to share de-identified data with academic partners under agreed terms.

Research Collaboration

A university lab created a template Approved DNA Agreement for multi-site studies to simplify IRB approvals and participant recruitment.

Streamlined multi-center sample transfers and tracking.
Standard terms for data sharing, commercialization options, and donor recontact reduced negotiation time, allowed faster sample pooling, and clarified rights for potential downstream IP, which accelerated publication timelines and grant reporting.

Vendor Pricing and Feature Snapshot for eSigning

Vendor feature comparison for executing Approved DNA Agreements. signNow is listed first to align vendor columns for easy technical evaluation.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by vendor	Varies by vendor	Varies by vendor	Varies by vendor
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No
Envelope Cap	No envelope cap	100 envelopes/user/year	Varies by plan	Varies by plan	Varies by plan

Frequently Asked Questions About Execution and Compliance

Answers to common questions about validity, consent scope, identity verification, and e-signing options for the Approved DNA Agreement.

Need help? Contact support

Is an electronic signature valid?
Yes — under the ESIGN Act and UETA, an electronic signature is enforceable if the signing shows intent, consent to electronic records, attribution to the signer, and the record can be retained and reproduced.
When is notarization or witnesses required?
Notarization or witnesses depend on state law and document purpose; some jurisdictions require notarized acknowledgements for certain legal filings, while consent forms rarely require notarization unless requested for evidentiary purposes.
How does donor withdrawal work?
Withdrawal typically stops future testing and sharing; samples already used or distributed may not be retractable. Agreements should define whether stored samples will be destroyed, de-identified, or retained for regulatory obligations and under what notice period.
Can minors or guardians provide consent?
Minors generally cannot consent for themselves; a parent or legal guardian must sign. Agreements should include fields for guardian identification and any assent procedures and follow applicable state laws governing research involving minors.
What methods verify signer identity?
Acceptable methods include government ID review, in-person verification, RON identity proofing, or multi-factor authentication for e-signatures. Level of verification should match sensitivity of genetic data and applicable privacy standards.
Does HIPAA apply to this agreement?
If the agreement involves protected health information in clinical settings, HIPAA applies and a business associate agreement may be required; research settings often require additional IRB and privacy safeguards beyond HIPAA.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now